Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 19, 2010 Travis Hoium	Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri.
The Motley Fool May 27, 2011 Brian Orelli	What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate.
The Motley Fool December 31, 2011 David Williamson	2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here?
The Motley Fool July 29, 2011 Sean Williams	Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling.
The Motley Fool September 17, 2010 Luke Timmerman	Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders?
The Motley Fool July 20, 2010 Jordan DiPietro	Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment.
The Motley Fool September 28, 2011 Brian Orelli	One Step Closer to an FDA Decision Cell Therapeutics is still risky, though.
The Motley Fool June 15, 2011 Brian Orelli	Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story.
The Motley Fool May 4, 2011 Brian Orelli	Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down.
The Motley Fool June 15, 2005 Brian Gorman	Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors.
The Motley Fool July 1, 2011 Brian Orelli	What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug."
The Motley Fool September 15, 2010 Brian Orelli	Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out.
The Motley Fool October 13, 2010 Matt Koppenheffer	Novavax Shares Popped: What You Need to Know Shares of biopharmaceuticals small fry Novavax jumped more than 10% in intraday trading on heavy volume.
The Motley Fool December 3, 2010 Travis Hoium	Orexigen Therapeutics Shares Plunged: What You Need to Know Shares of biopharmaceutical company Orexigen Therapeutics fell 10% today after a Food and Drug Administration announcement.
BusinessWeek September 29, 2003 Gene G. Marcial	Taking Aim at Cancer Cell Therapeutics isn't expected to make money until 2007, but Edward Hemmelgarn, president of Shaker Investments, is buying into the small-cap biotech anyway. Shaker already owns 1.7 million shares. Cell is developing cancer treatments that are less toxic but more effective, he says.
The Motley Fool July 30, 2010 Anand Chokkavelu	5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.
The Motley Fool July 26, 2010 Tom Gardner	A Disaster for Shareholders Two biotechnology stocks not worth the trouble.
The Motley Fool December 9, 2011 David Williamson	1 Biotech Soars While Another Crashes Cell Therapeutics dilutes shareholders while SIGA squashes fears.
The Motley Fool November 18, 2010 Travis Hoium	Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam.
The Motley Fool October 27, 2010 Matt Koppenheffer	Pacific Capital Bancorp Shares Plunged: What You Need to Know Is this meaningful? Or just another movement?
The Motley Fool December 22, 2010 Matt Koppenheffer	Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume.
The Motley Fool September 18, 2006 Brian Lawler	Cell Therapeutics' New Mate The biopharmaceutical company removes some uncertainty by teaming up with Novartis. Investors, take note.
The Motley Fool July 27, 2010 Brian Orelli	Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more?
The Motley Fool January 4, 2012 Brian Orelli	Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining.
The Motley Fool August 24, 2011 Brian D. Pacampara	United Therapeutics Shares Got Crushed: What You Need to Know Shares of drugmaker United Therapeutics plunged 17% today after its experimental orally administered lung drug failed in a late-stage clinical trial.
The Motley Fool May 26, 2009 Brian Orelli	A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents.
The Motley Fool December 11, 2007 Brian Orelli	Medicare Whacks Oncology Drugs Bad news for some pharmaceutical companies as Medicare announces it is reducing the reimbursement rate for two lymphoma drugs.
The Motley Fool July 13, 2011 David Williamson	Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of.
The Motley Fool October 18, 2011 Evan Niu	Halozyme Therapeutics Shares Surged: What You Need to Know Shares of Halozyme Therapeutics are surging by as much as 22.5% today on news that, together with partner Roche Holding, the company has reported positive results from a trial study regarding one of its drugs.
AskMen.com Dave Golokhov	Cell Phones And Cancer With so much money in the cell phone industry, it looks like straight answers regarding the risks will be hard to come by.
The Motley Fool August 31, 2005 Rich Smith	It's Not a Tumor Cell phones cause cancer, right? A new study suggests otherwise. Cell phone industry investors, rejoice!
The Motley Fool February 6, 2008 Brian Lawler	PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note.
BusinessWeek May 28, 2009 Catherine Arnst	Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs.
BusinessWeek April 23, 2007 Gene G. Marcial	Avalon's New Lab Partner: Merck Avalon pharmaceuticals, a little-known biopharma focusing on small-molecule therapeutics for cancer, has teamed up with Big Pharma, including Merck, for the use of its AvalonRx drug discovery system.
Registered Rep. February 1, 2005 Bob Hirschfeld	Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
AskMen.com Jacob Franek	Do Cell Phones Cause Cancer? The cellular phone is fast becoming the single most important piece of personal electronics - but at what cost and do cell phones cause brain cancer?
InternetNews March 23, 2009 Michelle Megna	Cell Phone Users Cutting Back in Harsh Economy The mobile industry will have to increasingly rely on smartphone sales as cell phone usage falls out of favor in souring economy.
The Motley Fool July 22, 2011 Anand Chokkavelu	9 Small Biotechs Near 52-Week Lows Here are nine companies in this space that are within 20% of their 52-week lows and have market caps between roughly $200 million and $500 million.
The Motley Fool December 23, 2011 Selena Maranjian	3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick.
The Motley Fool January 10, 2011 James Royal	Hit the Jackpot With These 7 Stocks These stocks have attracted enormous interest from investors, perhaps because many of the shares trade hands at just pennies a share.
The Motley Fool July 13, 2011 Sean Williams	Shareholders Should Fire These 3 CEOs Is it time for these CEOs to step aside in the name of progress?: Antonio Perez of Kodak... Stephan Elop of Nokia... James Bianco of Cell Therapeutics...
The Motley Fool August 21, 2008 Brian Lawler	PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
The Motley Fool December 18, 2008 Dan Caplinger	The Wrong Way to Invest Today Avoid the temptation to use volatility for short-term gains.
The Motley Fool September 2, 2011 Matt Koppenheffer	This Is How You Can Buy Happiness Are penny stocks the ultimate route to wealth and happiness?
The Motley Fool October 26, 2009 Adam J. Wiederman	Time to Sell and Lock in Your Gains With stocks up so much, it might be time to take some money off the table.
PC Magazine October 10, 2007 Gary Berline	Excel Tip: Cell Navigation Jump easily from one cell to a non-neighboring cell.
The Motley Fool May 2, 2011 Brian Orelli	StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies.
The Motley Fool February 2, 2006 Brian Gorman	Cambrex in a Crunch The drug manufacturer is suffering despite positive macro trends. For now, investors shouldn't expect much from Cambrex.
The Motley Fool December 31, 2011 Brian Orelli	3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012.